Medicare Enrolled
Dr. Michele Sartori, M.D.
Cardiovascular Disease · Houston, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sartori from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sartori? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sartori
Dr. Michele Sartori is a cardiovascular disease in Houston, TX, with 20 years in practice. Based on federal Medicare data, Dr. Sartori performed 4,056 Medicare services across 1,907 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sartori received a total of $226,749 from 68 pharmaceutical and/or device companies across 984 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sartori is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 24% volume in TX$ $226,749 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,056
Medicare services
Top 24% in TX for cardiovascular disease
1,907
Unique beneficiaries
$64
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~203 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Chronic care management, first 20 min/month | 951 | $48 | $66 |
| Office visit, established patient, complex (40-54 min) | 638 | $134 | $188 |
| Electrocardiogram (EKG), 12-lead | 635 | $11 | $19 |
| Hospital follow-up visit, moderate complexity | 271 | $59 | $76 |
| Remote pacemaker/defibrillator monitoring, 90 days | 143 | $17 | $28 |
| EKG interpretation and report | 141 | $6 | $9 |
| Hospital follow-up visit, high complexity | 125 | $85 | $111 |
| Echocardiogram, transthoracic | 117 | $154 | $234 |
| Heart muscle strain imaging | 96 | $29 | $42 |
| Initial hospital admission, moderate complexity | 94 | $105 | $142 |
| Regadenoson injection (Lexiscan) for heart stress test | 92 | $47 | $65 |
| Remote pacemaker monitoring, 90 days | 82 | $23 | $37 |
| Programming of dual lead pacemaker system | 79 | $48 | $65 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 65 | $20 | $38 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 58 | $27 | $39 |
| Ultrasound of leg arteries or artery grafts | 53 | $70 | $128 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 51 | $28 | $51 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 45 | $10 | $56 |
| New patient office visit (45-59 min) | 45 | $123 | $174 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 44 | $102 | $156 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 41 | $355 | $510 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 38 | $49 | $92 |
| Ultrasound study of arm and leg arteries | 37 | $59 | $89 |
| Ultrasound of leg arteries at rest and after exercise | 37 | $25 | $78 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 35 | $309 | $394 |
| Prothrombin time test (blood clotting) | 28 | $4 | $12 |
| Programming of dual lead implantable defibrillator system | 15 | $63 | $86 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.2% high complexity
10.8% medium
77.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$226,749
Total received (2018-2024)
Avg $32,393/year across 7 years
Top 2% in TX for cardiovascular disease
68
Companies
984
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$185,513 (81.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$39,981 (17.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,255 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$60,061
2023$45,983
2022$18,984
2021$44,737
2020$3,974
2019$24,377
2018$28,633
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$96,575
Esperion Therapeutics, Inc.
$54,854
SANOFI-AVENTIS U.S. LLC
$23,520
Abbott Laboratories
$18,972
Regeneron Healthcare Solutions, Inc.
$8,350
Janssen Pharmaceuticals, Inc
$4,054
Medtronic Vascular, Inc.
$3,725
Cardiovascular Systems Inc.
$2,474
AstraZeneca Pharmaceuticals LP
$1,489
ABIOMED
$1,439
Amgen Inc.
$971
Impulse Dynamics (USA) Inc.
$845
Boehringer Ingelheim Pharmaceuticals, Inc.
$709
Noven Therapeutics, LLC
$700
Actelion Pharmaceuticals US, Inc.
$674
Novartis Pharmaceuticals Corporation
$584
Medicure Pharma Inc.
$564
E.R. Squibb & Sons, L.L.C.
$490
Merck Sharp & Dohme LLC
$432
Medtronic, Inc.
$426
Chiesi USA, Inc.
$310
Siemens Medical Solutions USA, Inc.
$306
BOSTON SCIENTIFIC CORPORATION
$306
United Therapeutics Corporation
$258
Edwards Lifesciences Corporation
$255
Akcea Therapeutics, Inc.
$254
PFIZER INC.
$233
Boston Scientific Corporation
$192
Penumbra, Inc.
$179
MERZ NORTH AMERICA, INC.
$178
Shockwave Medical, Inc
$155
Kiniksa Pharmaceuticals International, plc
$148
Gilead Sciences, Inc.
$148
Bayer HealthCare Pharmaceuticals Inc.
$147
HeartFlow, Inc.
$138
Dexcom, Inc.
$129
Respicardia, Inc.
$123
Regeneron Pharmaceuticals, Inc.
$121
Amarin Pharma Inc.
$120
Lexicon Pharmaceuticals, Inc.
$117
Bayer Healthcare Pharmaceuticals Inc.
$108
BIOTRONIK INC.
$97
Lundbeck LLC
$88
Daiichi Sankyo Inc.
$72
SCPHARMACEUTICALS INC.
$69
Otsuka America Pharmaceutical, Inc.
$62
Kiniksa Pharmaceuticals, Ltd.
$55
Ethicon US, LLC
$44
ARALEZ PHARMACEUTICALS US INC.
$43
AngioDynamics, Inc.
$36
Cook Medical LLC
$35
ARBOR PHARMACEUTICALS, INC.
$35
Allergan Inc.
$33
Philips Electronics North America Corporation
$33
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$29
Bard Peripheral Vascular, Inc.
$28
Merck Sharp & Dohme Corporation
$25
HEARTFLOW, INC.
$25
Lilly USA, LLC
$22
CARDIVA MEDICAL, INC.
$18
AGEPHA Pharma FZ LLC
$18
Astellas Pharma US Inc
$18
iRhythm Technologies, Inc.
$18
Itamar Medical Inc
$16
CVRx, Inc.
$15
Coala Life Inc
$15
Inari Medical, Inc.
$14
Vifor Pharma, Inc.
$14
Top 3 companies account for 77.2% of total payments
Associated products mentioned in payments ›
ACCENT · ALPHAVAC · AMPLATZER AMULET · AMPLATZER Occluders · AMPLATZER Vascular Plug and Accs · ASSURITY · AVEIR · Accent Pacemaker · Adempas · Allura Xper FD 20 · Allure CRT Pacemaker · Allure Quadra RF CRT Pacemaker · Arcalyst · Artis icono floor · Asahi Fielder coronary guide wire · Assurity Pacemaker · BRILINTA · BYDUREON · BYSTOLIC · Barostim Neo System · CAMZYOS · CARDIVA VASCADE MVP VVCS 6-12F · CHANTIX · CLEVIPREX · Circulatory Support · Coala Heart Monitor · Confirm Rx · Connectivity and Remote care · Cook Medical Lead Management - Lead Extraction · CoreValve Evolut · Corlanor · Coronary Orbital Atherectomy System · DEXCOM CGM · DIAMONDBACK PERIPHERAL · DISEASE STATE · Diamondback Coronary · Diamondback Peripheral · Durata Defibrillation ICD Lead · ELIQUIS · EMBLEM · ENTRESTO · Edarbi · Ellipse ICD · EnSite Precision Cardiac Mapping System · FARXIGA · FFRct · FLOWTRIEVER CATHETER · FORTIFY ASSURA · FUROSCIX · Fortify Assura · GALLANT · GENERAL VASCULAR INTERVENTION · HeartMate 3 Left Ventricular Dev · Horizant · ICDs · INJECTAFER · INVOKANA · Impella · Indigo System · Inpefa · JARDIANCE · KENGREAL · Kerendia · LEQVIO · LEXISCAN · LINQ II · LODOCO · LifeVest · MERLIN@HOME · MULTAQ · Merlin Connectivity and Remote · NEXLETOL · NEXLIZET · NORTHERA · OPSUMIT · OPSUMIT MACITENTAN · OPTIMIZER · ORENITRAM · Omnilink Elite vascular stent system · Optimizer · Optis Coronary Imaging System · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Peripheral Orbital Atherectomy System · QUADRA ASSURA · Quadra Allure MP RF CRT Pacemkr · Quadra Assura CRT Defibrillator · Quartet CRT Lead · REMODULIN · RESOLUTE ONYX · ROTAPRO · Repatha · Resolute · Reveal LINQ · S · SAMSCA · SOLIQUA 100/33 · SURGICEL NU-KNIT · SYMPLICITY G3 · SYNERGY · TEGSEDI · TOUJEO · TYVASO · Tendril Pacing Lead · Tresiba · Turbo-Power · UNIFY ASSURA · UPTRAVI · Unify Assura CRT Defibrillator · VERQUVO · VIGILANT · VYNDAQEL · Vascepa · Vascular Lithotripsy · Veltassa · Verquvo · WATCHMAN FLX · WINREVAIR · WatchPAT · Wegovy · XARELTO · Xience Sierra Coronary Stent · Xience Sierra Coronary Stent System · Xience V coronary stent system · ZIO XT Patch · ZONTIVITY · ZYPITAMAG · ZYPITAMAG (pitavastatin) · Zilver PTX · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in cardiovascular disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for cardiovascular disease in TX.
Equivalent to $5,590 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
385
Per 100K population
8.1
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sartori is a clinical cardiology specialist, with above-average Medicare volume (top 24% in TX), and high industry engagement (speaking/promotional, top 2%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sartori experienced with chronic care management, first 20 min/month?
Based on Medicare claims data, Dr. Sartori performed 951 chronic care management, first 20 min/month services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sartori receive payments from pharmaceutical companies?
Yes. Dr. Sartori received a total of $226,749 from 68 companies across 984 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sartori's costs compare to other cardiovascular diseases in Houston?
Dr. Sartori's average Medicare payment per service is $64. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sartori) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Houston
Browse cardiovascular diseases in Houston ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
By company
Esperion Therapeutics, Inc. Payments to Doctors
See all physicians who received payments from Esperion Therapeutics, Inc..
By company
SANOFI-AVENTIS U.S. LLC Payments to Doctors
See all physicians who received payments from SANOFI-AVENTIS U.S. LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology